| pubmed-article:21067252 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21067252 | lifeskim:mentions | umls-concept:C0009247 | lld:lifeskim |
| pubmed-article:21067252 | lifeskim:mentions | umls-concept:C0009462 | lld:lifeskim |
| pubmed-article:21067252 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:21067252 | lifeskim:mentions | umls-concept:C0022661 | lld:lifeskim |
| pubmed-article:21067252 | lifeskim:mentions | umls-concept:C0403447 | lld:lifeskim |
| pubmed-article:21067252 | lifeskim:mentions | umls-concept:C0357126 | lld:lifeskim |
| pubmed-article:21067252 | lifeskim:mentions | umls-concept:C0937950 | lld:lifeskim |
| pubmed-article:21067252 | lifeskim:mentions | umls-concept:C1273870 | lld:lifeskim |
| pubmed-article:21067252 | lifeskim:mentions | umls-concept:C0205099 | lld:lifeskim |
| pubmed-article:21067252 | lifeskim:mentions | umls-concept:C0439836 | lld:lifeskim |
| pubmed-article:21067252 | lifeskim:mentions | umls-concept:C1514923 | lld:lifeskim |
| pubmed-article:21067252 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:21067252 | pubmed:dateCreated | 2010-12-15 | lld:pubmed |
| pubmed-article:21067252 | pubmed:abstractText | The management of anaemia in chronic kidney disease (CKD) to achieve current guideline goals is difficult and is hindered by multiple factors, including problems with the scheduling and adjustment of dosing of erythropoiesis-stimulating agents (ESAs) and the frequency of required ESA administration to achieve target haemoglobin (Hgb) levels. Objective: The primary objective of this study was to examine whether converting a large cohort of CKD patients receiving epoetin alfa to darbepoetin alfa would decrease the frequency of drug administration while permitting an acceptable management of CKD-related anaemia. | lld:pubmed |
| pubmed-article:21067252 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21067252 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21067252 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21067252 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21067252 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21067252 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21067252 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21067252 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21067252 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21067252 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21067252 | pubmed:issn | 1173-2563 | lld:pubmed |
| pubmed-article:21067252 | pubmed:author | pubmed-author:FinkelsteinFr... | lld:pubmed |
| pubmed-article:21067252 | pubmed:author | pubmed-author:SimonDavid... | lld:pubmed |
| pubmed-article:21067252 | pubmed:author | pubmed-author:GobinJayaJ | lld:pubmed |
| pubmed-article:21067252 | pubmed:author | pubmed-author:CerniiAuraA | lld:pubmed |
| pubmed-article:21067252 | pubmed:author | pubmed-author:McLeanRosella... | lld:pubmed |
| pubmed-article:21067252 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:21067252 | pubmed:volume | 31 | lld:pubmed |
| pubmed-article:21067252 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21067252 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21067252 | pubmed:pagination | 113-20 | lld:pubmed |
| pubmed-article:21067252 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:21067252 | pubmed:meshHeading | pubmed-meshheading:21067252... | lld:pubmed |
| pubmed-article:21067252 | pubmed:meshHeading | pubmed-meshheading:21067252... | lld:pubmed |
| pubmed-article:21067252 | pubmed:meshHeading | pubmed-meshheading:21067252... | lld:pubmed |
| pubmed-article:21067252 | pubmed:meshHeading | pubmed-meshheading:21067252... | lld:pubmed |
| pubmed-article:21067252 | pubmed:meshHeading | pubmed-meshheading:21067252... | lld:pubmed |
| pubmed-article:21067252 | pubmed:meshHeading | pubmed-meshheading:21067252... | lld:pubmed |
| pubmed-article:21067252 | pubmed:meshHeading | pubmed-meshheading:21067252... | lld:pubmed |
| pubmed-article:21067252 | pubmed:meshHeading | pubmed-meshheading:21067252... | lld:pubmed |
| pubmed-article:21067252 | pubmed:meshHeading | pubmed-meshheading:21067252... | lld:pubmed |
| pubmed-article:21067252 | pubmed:meshHeading | pubmed-meshheading:21067252... | lld:pubmed |
| pubmed-article:21067252 | pubmed:meshHeading | pubmed-meshheading:21067252... | lld:pubmed |
| pubmed-article:21067252 | pubmed:meshHeading | pubmed-meshheading:21067252... | lld:pubmed |
| pubmed-article:21067252 | pubmed:meshHeading | pubmed-meshheading:21067252... | lld:pubmed |
| pubmed-article:21067252 | pubmed:meshHeading | pubmed-meshheading:21067252... | lld:pubmed |
| pubmed-article:21067252 | pubmed:meshHeading | pubmed-meshheading:21067252... | lld:pubmed |
| pubmed-article:21067252 | pubmed:meshHeading | pubmed-meshheading:21067252... | lld:pubmed |
| pubmed-article:21067252 | pubmed:meshHeading | pubmed-meshheading:21067252... | lld:pubmed |
| pubmed-article:21067252 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21067252 | pubmed:articleTitle | Conversion from epoetin alfa to darbepoetin alfa for management of anaemia in a community chronic kidney disease centre: a retrospective cohort study. | lld:pubmed |
| pubmed-article:21067252 | pubmed:affiliation | Hospital of Saint Raphael, Metabolism Associates, Yale University, New Haven, Connecticut, USA. | lld:pubmed |
| pubmed-article:21067252 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21067252 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
